在耐火性膜性病中使用Obinutuzumab:一个案例系列
Yuxin Lin1, Quan Han1, Liangliang Chen1
1Kidney Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Nephrology, Zhejiang University, Hangzhou, China; National Key Clinical Department of Kidney Diseases, Hangzhou, China; Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China.
Kidney medicine
|August 5, 2024
概括
在膜性病 (MN) 患者中,OBINUTUZUMAB有效诱导了缓解,对那些对Rituximab无反应的患者尤其有希望. 治疗耐受性良好,在本病例系列中没有报告严重不良事件.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 膜性脏病 (MN) 是一种自身免疫性脏疾病.
- 反CD20单克隆抗体是MN的有效治疗方法.
- 与Rituximab相比,Obinutuzumab在其他B细胞恶性瘤中表现出更高的疗效.
研究的目的:
- 评估在患有膜性病症的患者中奥比努祖马布的疗效和安全性.
- 评估缓解率,缓解时间和无复发生存率.
- 为了比较obinutuzumab在接受或没有接受过rituximab治疗的患者中的有效性.
主要方法:
- 一个涉及18名用obinutuzumab治疗的MN患者的案例系列研究.
- 主要结局包括缓解率,首次缓解的时间和无复发的生存率.
- 使用考克斯模型,日志等级测试和卡普兰-梅尔分析的生存分析.
主要成果:
- 94.4%的患者实现了缓解,27.8%的患者实现了完全缓解.
- 缓解的中位时间为2.7个月,中位无复发生存时间为9.8个月.
- 所有12名先前接受Rituximab治疗的患者都实现了缓解,其中33.3%实现了完全缓解. 不良事件是轻微的.
结论:
- 奥比努图祖马布在诱导MN的缓解方面表现出有希望的疗效和安全性.
- 这种药物在对rituximab反应不满意的患者中特别有效.
- 需要进一步的研究,以在更大的受控研究中证实这些发现.
更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...